# Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients

> **NCT04555486** · PHASE1 · COMPLETED · sponsor: **Dicerna Pharmaceuticals, Inc., a Novo Nordisk company** · enrollment: 6 (actual)

## Conditions studied

- Primary Hyperoxaluria Type 3

## Interventions

- **DRUG:** DCR-PHXC
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT04555486
- **Lead sponsor:** Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-14
- **Primary completion:** 2021-09-07
- **Final completion:** 2021-09-07
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04555486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04555486, "Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04555486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*